Cytek Biosciences (NASDAQ:CTKB) Receives New Coverage from Analysts at Stephens

Stephens began coverage on shares of Cytek Biosciences (NASDAQ:CTKB – Free Report) in a research report sent to investors on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating and a $9.00 target price on the stock. A number of other brokerages also recently issued reports on CTKB. Piper Sandler decreased their price target on […]

Related Keywords

Canada ,Piper Sandler ,Ming Yan ,Cytek Biosciences ,Royal Bank ,Cytek Biosciences Inc ,Ameritas Investment Partners Inc ,Morgan Stanley ,Pricet Rowe Associates Inc ,Cytek Biosciences Company Profile ,Life Insurance Co ,Securities Exchange Commission ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Investment Partners ,Cytek Biosciences Daily ,Nasdaq Ctkb ,Ctkb ,Medical ,Initiated Coverage ,Stephens ,